Matthew K. Fust, Director at Ultragenyx Pharmaceutical Inc. (RARE), sold 16,890 shares at $50.89 ($859K) on 2024-03-07, disclosed to the SEC on 2024-03-11.
Scheduled sale ($859k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.85 | 2,145 | $109K | 12.7% |
| 2 | $50.85 | 2,145 | $109K | 12.7% |
| 3 | $50.88 | 7,500 | $382K | 44.4% |
| 4 | $50.89 | 2,550 | $130K | 15.1% |
| 5 | $50.89 | 2,550 | $130K | 15.1% |
| Total | $50.88 avg | 16,890 |
| $859K |
| 100% |
| Filing → |
| CRNX | SELL | 2024-03-22 | $2.1M | — | Filing → |
| CRNX | SELL | 2022-07-15 | $119K | — | Filing → |
| ATRA | SELL | 2021-11-05 | $260K | — | Filing → |